Security Guard

Healthcare stocks have gained 33.4% over the past six months, beating the S&P 500's 13.5% rise. Still, StockStory says heavy regulation makes the sector risky and names three stocks it is avoiding. Teleflex (NYSE:TFX), valued at $5.33 billion, makes single-use medical devices for critical care and surgery. It cites soft demand, earnings per share falling 6.5% a year over five years, and weak returns on capital. The stock trades at $125.70, or 13.6x forward earnings. Enovis (NYSE:ENOV), worth $1.05 billion, makes orthopedic devices. Sales were flat over five years while earnings per share fell 9.5% a year. Its shares trade at $18.26, or 5x forward earnings. Ocular Therapeutix (NASDAQ:OCUL), valued at $1.66 billion, develops sustained-release eye treatments. Sales fell 7.7% a year over two years, and earnings per share fell 7.5% a year over five.

North America leads Foot and Ankle Reconstruction devices market. Foot and ankle problems don't get the attention that hip and knee replacements do, but the devices used to fix them - plates, screws, fusion systems, total ankle implants - are quietly becoming one of the more dynamic corners of orthopedics. Here's where the market stands and where it's headed. Market Size and Growth Metrics The global foot and ankle reconstruction devices market was valued at USD 1.8 billion in 2025 and is estimated to reach USD 1.9 billion in 2026. From there, it's projected to climb to USD 3.3 billion by 2033, growing at a CAGR of 8.3% between 2026 and 2033 - nearly doubling in under a decade. What's fueling that growth: * An aging population with degenerative joint disease. The CDC estimated roughly 33 million U.S. adults were living with osteoarthritis by the end of 2024, and the Osteoarthritis Action Alliance projects that figure will hit 72 million by 2030 and 78 million by 2040. Around 25% of ankle fractures in patients over 60 are linked to osteoporosis, and ankle osteoarthritis affects an estimated 3.4% of the global adult population - all of which translates into steady surgical demand. * Minimally invasive techniques going mainstream. Surgeons are shifting toward smaller incisions, faster recovery, and procedure-specific instrumentation for tendon repairs, fusions, and osteotomies. * Smarter surgical technology. Computer-assisted navigation, AI-driven imaging interpretation, and predictive planning tools are improving implant placement accuracy and reducing revision rates. By the numbers: * North America led all regions with a 47.9% revenue share in 2025, backed by strong reimbursement systems and high procedure volumes; the U.S. is the largest single country market. * Hallux valgus (bunion) correction was the top application segment at 31.4% share in 2025, though hammertoe correction is expected to grow fastest through the forecast period. * Hospitals captured 59.7% of end-use revenue in 2025, while outpatient/ambulatory surgical centers are the fastest-growing setting, as more elective reconstruction procedures move out of inpatient settings entirely. One notable headwind: regulatory complexity. Compliance with FDA requirements, EU MDR 2017/745, and region-specific approval pathways adds significant time and cost to bringing new implants to market - a burden that falls hardest on smaller manufacturers. Competitive Landscape and Core Players The market splits fairly cleanly into two tiers. Established multinational players - Stryker, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, Smith+Nephew, and Arthrex - compete on scale: broad product portfolios spanning trauma, reconstruction, and sports medicine; deep clinical evidence; global distribution; and long-standing surgeon relationships. Their weakness is largely structural - premium pricing and complex regulatory overhead can limit adoption in cost-sensitive settings. Emerging and specialized players - Globus Medical, Orthofix, Enovis, Acumed, CONMED, and Anika Therapeutics - compete on agility, focusing on procedure-specific fixation systems, orthobiologics, and minimally invasive implants. They move faster on niche innovation but lack the global footprint and hospital procurement relationships of the majors. Recent activity shows both tiers pushing hard on product launches: * Stryker expanded its Foot & Ankle portfolio in the U.S. (September 2024) with the Osteotomy Truss System and Ankle Truss System for fusion and total ankle procedures. * DePuy Synthes launched the TriLEAP Lower Extremity Anatomic Plating System (August 2025) for forefoot and midfoot reconstruction. * Zimmer Biomet and Treace Medical Concepts both showcased updated bunion-correction and total ankle systems at the AOFAS Annual Conference in September 2025. * Fusion Orthopedics acquired Metalogix External Fixation Systems (January 2025), adding external fixation frames and mini-rail systems to its lineup - a sign that M&A activity, while moderate overall, is still reshaping portfolios. Competitive advantage increasingly hinges on demonstrable clinical outcomes and comprehensive, procedure-specific offerings that bundle implants, biologics, and digital surgical planning together, rather than any single device. Product Specifications and Innovation Highlights Reconstruction devices in this market are segmented by the specific anatomical problem they solve. Hallux Valgus/Bunion Correction devices include plates, screws, staples, and intramedullary fixation and osteotomy implants, all designed to realign the first metatarsal and great toe. Hammertoe Correction relies on intramedullary implants, fixation pins, screws, and fusion systems to realign and stabilize the affected interphalangeal joints. Midfoot Reconstruction uses fusion plates, locking screws, and compression staples to stabilize the tarsometatarsal and naviculocuneiform joints following trauma, arthritis, or Charcot foot. Hindfoot & Ankle Reconstruction devices - arthrodesis plates, intramedullary nails, locking screws, and compression systems - restore alignment and stability in severe arthritis, instability, or post-traumatic cases. Total Ankle Replacement (TAR) implants use prosthetic tibial and talar components to replace the damaged joint while preserving natural motion, offering an alternative to fusion for end-stage arthritis. Toe Joint Replacement systems, primarily targeting the first metatarsophalangeal (MTP) joint, use artificial joint implants to restore mobility and relieve pain in arthritic or degenerated toes. Some recent product specifics worth noting: * SINTX Technologies' SINAPTIC Foot & Ankle Osteotomy Wedge System (FDA-cleared October 2025) is made from silicon nitride, engineered specifically for hallux valgus precision. * Medline UNITE's REFLEX HYBRID Nitinol Implant System (FDA 510(k), April 2025) combines locking plate stability with nitinol staple compression for MTP fusions and Lapidus procedures. * Forma Medical's OptimalHT system (2023) brought dedicated minimally invasive instrumentation to hammertoe correction, a segment that had lagged behind bunion surgery in MIS adoption. * NovaBone's bioglass syringes (2.5cc/5cc) target bone defect repair and osseointegration as an adjunct to hardware-based fixation. The throughline across nearly every recent launch is anatomical specificity paired with less invasive delivery - implants engineered for one exact procedure rather than general-purpose hardware, combined with smaller incisions and faster weight-bearing timelines. This market rewards companies that can pair strong clinical data with genuinely differentiated, procedure-specific hardware - a pattern likely to hold as the patient population driving demand (older, more diabetic, more active later in life) continues to grow. Customize This Report - get 20% free customization to tailor scope, segments, or regions to your needs Matched content.

Transient troubles shake up European market. by Mike Evers on September 15, 2026 The orthopedic market in Western Europe has shifted significantly over the last few years. In 2024, orthopedic procedure volumes were still rebounding from the disruption of the pandemic and Europe was driving significant growth. "The volumes outside the U.S. remain very strong, in particular in Europe," said Zimmer Biomet CEO Ivan Tornos in mid-2024. "Within Europe there is a prominent backlog. So, market dynamics are very healthy, more in EMEA than APAC, but very healthy overall." That strength persisted through much of 2025. Stryker called Europe a "growth engine" and said it had a huge opportunity to increase international penetration of the best-performing U.S. products. Both Medacta and Medartis saw their EMEA sales take off in the wake of the pandemic. CONMED's growth rate in EMEA has outpaced its growth rate in the United States over the last 10 years. Enovis used its aggressive M&A strategy to rapidly globalize and surpass $1 billion in annual reconstructive sales. In recent years, the company purchased European players like Mathys, Novastep and LimaCorporate. Today, international sales make up 53% of Enovis' total recon revenue. However, the European market has slowed significantly in 2026. "I would say it's more weighted to the transient," said Enovis CEO Damien McDonald. "Strikes, fires, heat waves, all of those things, we believe, are transient. Ultimately, you keep the patient in the funnel. The only thing for me is sentiment as the war in the Middle East continues, and what does that do as people reorient funding towards military spend versus health care. We haven't seen any of that read through, but that's the watch out." Below, Orthoworld'll take a look at some of the factors Mr. McDonald mentioned and how they're impacting the Western European orthopedic market. Strikes limit procedure capacity and extend wait times. European healthcare strikes and labor actions have come to a head due to wage disputes, staff shortages, burnout and rapidly rising demand. These factors are pushing up against government efforts to control healthcare costs. The U.K. experienced repeated resident doctor strikes, with the most recent action taking place in April 2026. The walkout cost the country an estimated £3 billion over the course of three years due to canceled procedures, rescheduling, overtime and higher-cost replacement staff. The procedure bottleneck in the U.K. goes beyond labor unrest. Highly specialized clinical roles are struggling to meet demand. A report from the Royal College of Anaesthetists estimated that staffing shortages were preventing 1.5 million procedures annually. Healthcare strikes in Spain are more variable and diffused across regions. In Rioja, for instance, strikes in 2026 caused the suspension of 39,000 consultations and 1,200 surgical procedures. More than 8,500 patients were awaiting surgery, and the average surgical wait time grew to 86 days. Orthopedic procedures are predominantly elective, and are therefore easily postponed. But, as Orthoworld saw during the pandemic, many of these patients remain in the funnel and eventually have their surgery done. However, not every orthopedic company is robust enough to withstand an extended downturn in procedure volume. Ongoing disruption in a market like Europe could have strategic implications for even the largest players. The Iran war impact is far-reaching. One of the most prevalent indirect impacts from the Iran war is the shock to energy prices. Oil prices are well above $100 per barrel in September of 2026. European natural gas prices have surged amid fears about Middle Eastern exports and winter storage. Increasing energy prices could further tax hospitals with already limited budget flexibility. The conflict has disrupted trade routes and increased transportation costs, which compound already inflated energy prices. In March, the World Health Organization warned that supply chain disruption can limit access to essential medicines and medical supplies. For orthopedic companies, the risk is spread across a wide array of categories including but not limited to polymer components, packaging, electronic components for robotics and navigation, as well as coatings and specialty materials. An increasingly unstable geopolitical climate has also caused defense spending in Europe to compete with limited fiscal space. There isn't a one-to-one trade-off between defense and healthcare, but Orthoworld is seeing some countries constrain healthcare spending while expanding defense spending. France's 2026 government budget included £5 billion in healthcare-related reductions or cost-containment measures, including higher deductibles, more oversight of long-term illness coverage and reductions in hospital operation costs. Per Le Monde, French public hospitals were already carrying a £3 billion deficit. Concurrently, France's 2026 fiscal plan called for £6.5 billion in additional defense spending. In the wake of Russia's invasion of Ukraine, Finland plans to increase defense spending despite ongoing austerity measures. The country intends to further cut healthcare and social services to reduce the fiscal deficit and rising public debt. Reuters reported that the healthcare and social services reductions were part of the fiscal consolidation program to facilitate increased defense spending. The picture in the U.K. and Germany is more nuanced. Defense spending is increasing, but not directly at the expense of healthcare. However, the expanded footprint of defense in budgets can crowd out other services and apply more pressure to patients as adjacent social services are reduced. The road ahead. Orthoworld agree with Mr. McDonald that these troubles are likely transient. Or, at least, some of them are. Fiscal policy isn't something that can change overnight. Orthoworld learned during the period from 2020 to 2022 that orthopedic patients tend to be sticky. They defer procedures for a long time, but ultimately, they return since they're not going to get better otherwise. Companies that can demonstrate greater efficiency in the operation room and provide better value-based solutions will have a strategic advantage in the European market of the near future. Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.